echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Express second-line treatment of liver cancer, Keytruda combination achieves the primary endpoint of Phase 3 clinical trials

    Express second-line treatment of liver cancer, Keytruda combination achieves the primary endpoint of Phase 3 clinical trials

    • Last Update: 2022-02-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec Content Team Editor Merck & Co.
    (MSD) recently announced that its anti-PD-1 therapy Keytruda, in combination with best supportive care (BSC), has been used in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib in Asia.
    In patients, compared with placebo + BSC, patients' overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were significantly improved
    .

    Liver cancer is one of the leading causes of cancer-related deaths worldwide
    .

    It is estimated that in 2020, there will be more than 905,000 new cases of liver cancer worldwide, and more than 830,000 people will die from the disease
    .

    An estimated 75% to 90% of primary liver cancer cases are hepatocellular carcinoma
    .

    Worldwide, the main factors that increase the risk of hepatocellular carcinoma are chronic hepatitis B and C, alcohol consumption, and metabolic syndrome
    .

    Keytruda is an anti-PD-1 monoclonal antibody therapy that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes
    .

    Merck currently has more than 1,600 trials investigating the efficacy of Keytruda in a variety of cancers and treatment settings
    .

    The randomized, double-blind, placebo-controlled Phase 3 clinical trial, called KEYNOTE-394, was conducted in Asian patients
    .

    They had advanced hepatocellular carcinoma and had been treated with sorafenib or oxaliplatin-based chemotherapy
    .

    The trial results showed that Keytruda+BSC reduced the risk of death by 21% compared with placebo+BSC (HR=0.
    79, 95% CI, 0.
    63-0.
    99; p=0.
    0180)
    .

    Median OS was 14.
    6 months (95% CI, 12.
    6-18.
    0) for patients treated with Keytruda+BSC compared with 13.
    0 months (95% CI, 10.
    5-15.
    1) for patients treated with placebo+BSC
    .

    In addition, Keytruda+BSC reduced the risk of disease progression or death by 26% (HR=0.
    74, p=0.
    0032)
    .

    The ORR was 12.
    7% in the Keytruda+BSC arm and 1.
    3% in the placebo+BSC arm
    .

    In terms of safety, treatment-related adverse events (TRAEs) occurred in 66.
    9% of patients in the Keytruda+BSC group and 49.
    7% of the patients in the placebo+BSC group, and 14.
    4% of the patients in the Keytruda+BSC group and 5.
    9% of the patients in the placebo+BSC group.
    The patient developed grade 3-5 TRAE, please refer to reference [1] for detailed data
    .

    "Patients with advanced hepatocellular carcinoma continue to have a high unmet medical need and poor survival," said Dr.
    Scot Ebbinghaus, vice president of clinical research at Merck Laboratories
    .
    "
    We are pleased to share these new data from KEYNOTE-394 and are An extensive global hepatocellular carcinoma R&D program advances research in patients with this difficult-to-treat cancer
    .

    "Reference: [1] Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib.
    Retrieved January 19, 2022, from https://www.
    merck.
    com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/ Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research
    .

    This article is for information exchange purposes only.
    The views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views in the article
    .

    This article is not a treatment Program recommendation
    .

    If you need treatment program guidance, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.